Cystic Fibrosis–Associated Liver Disease in Lung Transplant Recipients

Cystic fibrosis (CF) is an autosomal recessive disease characterized by mutations in the gene that encodes for the cystic fibrosis transmembrane conductance regulator protein (CFTR). CFTR gene mutations manifest as epithelial cell dysfunction in the airways, biliary tract, pancreas, gut, sweat glands, paranasal sinuses, and genitourinary tract. The clinical manifestations of this dysfunction include respiratory tract infections, bronchiectasis, pancreatic insufficiency, malabsorption, intestinal obstruction, liver disease, and male infertility. The liver disease manifestations of CF can include biliary disease, multilobular cirrhosis, and portal hypertension with and without cirrhosis. Pulmonary disease is the main cause for morbidity and mortality in individuals with CF, and according to the International Society for Heart and Lung Transplantation, CF is the third most common indication for lung transplantation in adults, accounting for 16% of procedures performed. The survival after lung transplantation in individuals with CF continues to improve and is now the highest among end‐stage lung diseases requiring transplant. The survival rate at 10 years is close to 50%. Given the potential presence of liver disease in CF patients undergoing an evaluation for lung transplantation and in lung transplant recipients, it is important to understand the manifestations of liver disease in CF patients and the recommended workup and follow‐up. This review aims to discuss the current literature and provide guidance in the management of these patients.

[1]  M. Stanbrook,et al.  VX-659–Tezacaftor–Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles , 2020, Canadian Journal of Respiratory, Critical Care, and Sleep Medicine.

[2]  T. Alexopoulos,et al.  Evaluation of noninvasive markers for the diagnosis of cystic fibrosis liver disease , 2018, Scandinavian journal of gastroenterology.

[3]  F. van Goor,et al.  VX‐445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles , 2018, The New England journal of medicine.

[4]  B. Meiser,et al.  The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan Transplantation. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  A. Ba-Ssalamah,et al.  The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study , 2018, European Radiology.

[6]  F. Lehner,et al.  The liver-first approach for combined lung and liver transplantation , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  S. Davison Assessment of liver disease in cystic fibrosis. , 2018, Paediatric respiratory reviews.

[8]  C. Koh,et al.  Liver disease in patients with cystic fibrosis , 2018, Current opinion in gastroenterology.

[9]  S. Knechtle,et al.  Single-Center Long-Term Analysis of Combined Liver-Lung Transplant Outcomes , 2018, Transplantation direct.

[10]  Sherie J Smith,et al.  Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. , 2018, The Cochrane database of systematic reviews.

[11]  M. Guill,et al.  Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis , 2018, Annals of the American Thoracic Society.

[12]  J. Pilewski,et al.  Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[13]  H. Grasemann CFTR Modulator Therapy for Cystic Fibrosis. , 2017, The New England journal of medicine.

[14]  G. Snell,et al.  The evolution of lung transplantation for cystic fibrosis: A 2017 update. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[15]  J. Hoofnagle,et al.  Adult‐onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity , 2017, Hepatology.

[16]  E. Roeb,et al.  Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study , 2017, PloS one.

[17]  G. Casazza,et al.  Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis. , 2017, The Cochrane database of systematic reviews.

[18]  M. Davenport,et al.  King's Variceal Prediction Score: A Novel Noninvasive Marker of Portal Hypertension in Pediatric Chronic Liver Disease , 2017, Journal of pediatric gastroenterology and nutrition.

[19]  R. Houwen,et al.  Current and future therapies for inherited cholestatic liver diseases , 2017, World journal of gastroenterology.

[20]  S. McColley,et al.  Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del‐CFTR , 2017, Annals of the American Thoracic Society.

[21]  J. Bosch,et al.  Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases , 2017, Hepatology.

[22]  R. Houwen,et al.  Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[23]  K. Setchell,et al.  Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease. , 2016, The Journal of pediatrics.

[24]  D. Waltz,et al.  Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. , 2016, The Lancet. Respiratory medicine.

[25]  A. Geerts,et al.  Longitudinal Transient Elastography Measurements Used in Follow-up for Patients with Cystic Fibrosis. , 2016, Ultrasound in medicine & biology.

[26]  M. Egan Genetics of Cystic Fibrosis: Clinical Implications. , 2016, Clinics in chest medicine.

[27]  E. Kerem,et al.  Hepatopulmonary Syndrome in Patients With Cystic Fibrosis and Liver Disease. , 2016, Chest.

[28]  G. Tomlinson,et al.  Effects of Recipient Age and Diagnosis on Health-related Quality-of-Life Benefit of Lung Transplantation. , 2015, American journal of respiratory and critical care medicine.

[29]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[30]  G. A. Whitmore,et al.  A contemporary survival analysis of individuals with cystic fibrosis: a cohort study , 2014, European Respiratory Journal.

[31]  V. Ng,et al.  Simultaneous liver-pancreas transplantation for cystic fibrosis-related liver disease: a multicenter experience. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[32]  M. Narkewicz,et al.  Cirrhosis and other liver disease in cystic fibrosis. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[33]  T. Remmington,et al.  Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. , 2013, Paediatric respiratory reviews.

[34]  Melissa R. Miller,et al.  Pulmonary function in individuals who underwent liver transplantation: From the US cystic fibrosis foundation registry , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[35]  J. Hodson,et al.  Long‐Term Impact of Liver Transplantation on Respiratory Function and Nutritional Status in Children and Adults With Cystic Fibrosis , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[36]  P. Burgel,et al.  Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation. , 2011, Journal of hepatology.

[37]  B. Strandvik,et al.  Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[38]  J. Pilewski,et al.  Does simultaneous lung-liver transplantation provide an immunologic advantage compared with isolated lung transplantation? , 2011, The Journal of thoracic and cardiovascular surgery.

[39]  K. Reddy,et al.  Liver transplantation in patients with cystic fibrosis: Analysis of united network for organ sharing data , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[40]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[41]  M. Corey,et al.  Genetic modifiers of liver disease in cystic fibrosis. , 2009, JAMA.

[42]  F. Algar,et al.  Results of lung transplantation in patients with cystic fibrosis. , 2008, Transplantation proceedings.

[43]  C. Goss,et al.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. , 2007, American journal of respiratory and critical care medicine.

[44]  S. Gandhi,et al.  Lower Incidence of Bronchiolitis Obliterans in Pediatric Liver−Lung Transplant Recipients With Cystic Fibrosis , 2007, Transplantation.

[45]  A. Befeler,et al.  High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis , 2007, Current gastroenterology reports.

[46]  A. Morabito,et al.  Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome , 2002, Hepatology.

[47]  R. Calne Immunological tolerance: the liver effect , 2002, Immunological reviews.

[48]  B. Strandvik,et al.  Natural history of liver disease in cystic fibrosis , 1999, Hepatology.

[49]  R. Kotloff,et al.  Lung transplantation for cystic fibrosis. , 1998, Clinics in chest medicine.

[50]  S. Schwarzenberg,et al.  Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis , 2018, Journal of pediatric gastroenterology and nutrition.

[51]  D. Al-Adra,et al.  Combined lung-liver-pancreas transplantation in a recipient with cystic fibrosis. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[52]  E. Ingenito,et al.  Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del , 2017, The New England journal of medicine.

[53]  R. Gruessner,et al.  Survival of cystic fibrosis patients undergoing liver and liver-lung transplantations. , 2013, Transplantation proceedings.

[54]  D. Ashby,et al.  Ursodeoxycholic acid for cystic fibrosis-related liver disease. , 2012, The Cochrane database of systematic reviews.

[55]  S. Keshavjee,et al.  Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosis‐associated liver cirrhosis * , 2012, Clinical transplantation.

[56]  K. Lindor,et al.  What's Hot in the Red Journal This Month , 2011, The American Journal of Gastroenterology.